SCHEMBL19481706

SCHEMBL19481706

CCN1CC[C@@H](c2ccc(-c3cc4c(N5CCN(C(=O)C6CC6)CC5)ccnn4c3)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 5/20 0.37
LMNA P02545 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
USP2 O75604 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 3/20 0.37
TP53 P04637 2/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RET P07949 3/20 0.36
IDE P14735 1/20 0.36
GAA P10253 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19481699 1.00 KIT (0.38) KITALDH1A1MAPTLMNATDP1
SCHEMBL19481701 1.00 KIT (0.38) KITALDH1A1MAPTLMNATDP1
SCHEMBL19481764 0.96 ALDH1A1 (0.39) KITALDH1A1MAPTLMNATDP1
SCHEMBL19481769 0.95 PROKR1 (0.40) KITALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL19481771 0.95 PROKR1 (0.40) KITALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL19481755 0.95 PROKR1 (0.40) KITALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL19481681 0.95 ALDH1A1 (0.39) KITALDH1A1MAPTLMNATDP1
SCHEMBL19481954 0.92 ALDH1A1 (0.37) KITALDH1A1MAPTLMNATDP1
SCHEMBL19481793 0.92 IDE (0.40) KITALDH1A1MAPTLMNATDP1
SCHEMBL19481757 0.91 RET (0.36) KITRETJAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 WO disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 KIT 189/4885ALDH1A1 3277/4885MAPT 3886/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 KIT 189/4885ALDH1A1 3277/4885MAPT 3886/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 KIT 189/4885ALDH1A1 3277/4885MAPT 3886/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 KIT 27/4885ALDH1A1 2488/4885MAPT 3683/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 KIT 189/4885ALDH1A1 3277/4885MAPT 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.